- Opinion
- [Reporter’s View] Patience is a virtue...for drugs?
- by Eo, Yun-Ho Apr 20, 2022 06:05am
- Price falls when supply increases. The same goes for the pharmaceutical market. Although the government can reduce fiscal spending by inducing competition between pharmaceutical companies, this would lead to a delay in NHI reimbursement listing. As we enter the era of high-priced drugs, the government has been exercising the ‘art of
- Opinion
- [Desk] R&D capabilities and Moonshot
- by Chon, Seung-Hyun Apr 19, 2022 05:52am
- Pfizer CEO Albert Bourla introduced Pfizer's COVID-19 vaccine development process through a recently published book called "Moonshot." Every step from the decision to develop a COVID-19 vaccine to clinical trials, large-scale production, and transportation was close to impossible, and it created a miracle with prepared R&D capabilities and ju
- Opinion
- [Reporter's eyes] Despite Tessentrick's high sales
- by Apr 15, 2022 06:03am
- According to Roche audit report, the company recorded sales of 343.9 billion won and operating losses of 69.6 billion won last year. Sales fell 22.5% year-on-year, and operating losses increased. This is the first drop in sales in 10 years for Roche Korea, which has increased its sales every year. It is the largest deficit in 10 years. Roc
- Opinion
- [Reporter’s View] Deleting exemptions for industry dev.
- by Lee, Jeong-Hwan Apr 7, 2022 06:10am
- Until now, the pharmaceutical authorities had partially exempted the safety and efficacy review for ETCs and OTCs listed on drug formularies of 8 advanced countries &8211; the US, Japan, UK, Germany, France, Italy, Switzerland, and Canada - for the prompt introduction of drugs to Korea. This special exemption system for drugs listed in f
- Opinion
- [Reporter’s View] Still no news on SGLT-2 combo reimb.
- by Eo, Yun-Ho Apr 6, 2022 06:06am
- Still no news nor progress has been made on the discussions regarding reimbursement of combination therapies using SGLT-2 inhibitors. After a long three years, the Health Insurance Review and Assessment Service called for a diabetes expert meeting to discuss expanding reimbursement of SGLTL-2 inhibitors in September last year. At the meet
- Opinion
- [Reporter's view] Commercialization of innovative new drugs
- by Lee, Tak-Sun Apr 5, 2022 05:58am
- iLast month, immuno-cancer drug Keytruda was listed as the primary treatment for non-small cell lung cancer patients, and this month, the first chemical antigen receptor-T cell therapy (CAR-T) Kymirah received insurance benefits. Innovative treatments using patient immunity have succeeded in commercializing them in Korea one after another. The
- Opinion
- [Reporter’s View] Regrets in GOV's COVID-19 responses
- by Mar 30, 2022 06:09am
- “Gullmoosae” is a newly coined Korean word commonly used by stock investors to refer to investors who have lingering buy/sell regrets. The word is a combination of the Korean word ‘~halgul (should've)’ and the bird ‘engmossae (parrot),’ which describes the individual investor who regrets the past every time without buying or selling in
- Opinion
- [Reporter’s View] Specific healthcare plans are required
- by Lee, Jeong-Hwan Mar 24, 2022 05:54am
- President-elect Suk-Yeol Yoon’s transition committee has officially started working. Due to the COVID-19 pandemic, Yoon’s transition committee has opted to separately establish a special committee for COVID-19 response and operate the healthcare sector through the subcommittee for social affairs, welfare and culture. Therefore, policies on
- Opinion
- [Reporter's view] Our attitude toward personalized txs
- by Eo, Yun-Ho Mar 23, 2022 05:51am
- These drugs such as HER2, ALK, EGFR, and ROS1 are keywords that appear more frequently in recent articles related to anticancer drugs Effective treatments for patients vary depending on what genetic mutations the patient has. Starting with treatment HER2, ALK, EGFR, etc., which show excellence in patients in certain conditions, drugs targeti
- Opinion
- [Reporter’s View] Keytruda’s ‘trade-off’ reimbursement
- by Eo, Yun-Ho Mar 7, 2022 05:49am
- At last, Keytruda was finally approved to extend its reimbursement to first-line in lung cancer. However, whispers are rising on its approval, which was made four long years after the company applied for its reimbursement. The keyword is ’trade-off.’ Trade-offs, which refer to the policy direction in which pharmaceutical companies who
